BONNEY MICHAEL W 4

What Happened
Michael W. Bonney, a director of Autolus Therapeutics plc, was granted two derivative awards on June 29, 2026: 31,667 and 47,500 restricted stock units (RSUs), for a total of 79,167 RSUs. Each award was recorded at $0.00 per share (no immediate cash exchanged) and is reported as an award/grant (Form 4 code A). These are compensatory awards rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-29; Form 4 filed 2026-07-01 (no late filing indicated).
• Award type/code: A = Grant/Award of RSUs (derivative).
• Shares granted: 31,667 RSUs and 47,500 RSUs, total 79,167 RSUs; reported price $0.00; immediate reported value $0.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnotes of note:
  • F1: Each RSU is a contingent right to receive one American Depositary Share (ADS); each ADS is convertible into one Ordinary Share.
  • F2: These RSUs vest in one installment on June 29, 2027.
  • F3: Related share options (if held) vest in twelve equal monthly installments beginning July 29, 2026.

Context
RSU grants are typically part of compensation and do not represent an outlay of cash by the insider; they vest in the future (here, one-year cliff vesting on 2027-06-29), at which point the RSUs may convert into ADSs/ordinary shares. Such awards are routine executive/director compensation and should not be read alone as a definitive bullish or bearish signal.